12. SEGMENTS

6 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

SEGMENTS

12. SEGMENTS

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

The following tables set forth certain information regarding our segments:

	Six Months Ended September 30,
	2020			2019
Revenues:
Aethlon	$	–		$	30,000
ESI		–			–
Total Revenues	$	–		$	30,000
Operating Losses:
Aethlon	$	(3,173,367	)	$	(3,256,142	)
ESI		(8,440	)		(12,249	)
Total Operating Loss	$	(3,181,807	)	$	(3,268,391	)
Net Losses:
Aethlon	$	(3,174,095	)	$	(3,761,662	)
ESI		(8,440	)		(12,249	)
Net Loss Before Non-Controlling Interests	$	(3,182,535	)	$	(3,773,911	)
Cash:
Aethlon	$	14,473,035		$	785,461
ESI		197			197
Total Cash	$	14,473,232		$	785,658
Total Assets:
Aethlon	$	15,056,193		$	1,281,593
ESI		197			197
Total Assets	$	15,056,390		$	1,281,790
Capital Expenditures:
Aethlon	$	23,137		$	119,981
ESI		–			–
Capital Expenditures	$	23,137		$	119,981
Depreciation and Amortization:
Aethlon	$	18,041		$	5,751
ESI		–			–
Total Depreciation and Amortization	$	18,041		$	5,751
Interest Expense:
Aethlon	$	(728	)	$	(54,106	)
ESI		–			–
Total Interest Expense	$	(728	)	$	(54,106	)